Q1 Earnings Estimate for Adicet Bio Issued By HC Wainwright

Adicet Bio, Inc. (NASDAQ:ACET) – Stock analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for Adicet Bio in a research note issued on Monday, March 23rd. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($2.80) for the quarter, up from their prior forecast of ($2.91). HC Wainwright currently has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Adicet Bio’s current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Adicet Bio’s Q2 2026 earnings at ($2.87) EPS, Q3 2026 earnings at ($2.93) EPS, Q4 2026 earnings at ($2.99) EPS and FY2026 earnings at ($11.58) EPS.

Several other brokerages also recently weighed in on ACET. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adicet Bio in a report on Tuesday, January 27th. Canaccord Genuity Group set a $18.00 price objective on shares of Adicet Bio and gave the company a “buy” rating in a research note on Tuesday, January 6th. Truist Financial upgraded shares of Adicet Bio to a “strong-buy” rating in a research report on Wednesday. Finally, Guggenheim reduced their target price on shares of Adicet Bio from $128.00 to $100.00 and set a “buy” rating for the company in a research note on Friday, March 13th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $56.25.

Adicet Bio Trading Down 1.2%

Shares of ACET stock opened at $6.73 on Wednesday. The company has a market capitalization of $64.61 million, a P/E ratio of -0.37 and a beta of 1.56. The business’s 50 day moving average is $7.41 and its two-hundred day moving average is $9.78. Adicet Bio has a twelve month low of $6.41 and a twelve month high of $17.44.

Adicet Bio (NASDAQ:ACET) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($2.94) EPS for the quarter, beating the consensus estimate of ($3.23) by $0.29.

Institutional Investors Weigh In On Adicet Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of ACET. Goldman Sachs Group Inc. boosted its position in shares of Adicet Bio by 1.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 3,816,556 shares of the company’s stock worth $2,882,000 after purchasing an additional 63,691 shares in the last quarter. Two Sigma Investments LP increased its holdings in shares of Adicet Bio by 66.6% in the 3rd quarter. Two Sigma Investments LP now owns 854,568 shares of the company’s stock valued at $692,000 after purchasing an additional 341,761 shares in the last quarter. Franklin Resources Inc. purchased a new position in shares of Adicet Bio in the 4th quarter valued at about $5,276,000. Citadel Advisors LLC lifted its stake in shares of Adicet Bio by 19.8% in the third quarter. Citadel Advisors LLC now owns 583,948 shares of the company’s stock valued at $473,000 after purchasing an additional 96,342 shares during the period. Finally, Wealthedge Investment Advisors LLC boosted its holdings in Adicet Bio by 37.4% during the second quarter. Wealthedge Investment Advisors LLC now owns 313,108 shares of the company’s stock worth $191,000 after buying an additional 85,307 shares in the last quarter. Institutional investors and hedge funds own 83.89% of the company’s stock.

About Adicet Bio

Adicet Bio, Inc (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.